Press Releases

Date Title and Summary  
Toggle Summary Research Indicates Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Study Findings Could Mean Significantly Lower Doses and/or Shorter Courses of Immunosuppression for Patients Treated with GRNOPC1 MENLO PARK, Calif., June 11, 2007 – Geron Corporation (Nasdaq: GERN) today announced the presentation of research studies indicating that GRNOPC1, the company’s human
Toggle Summary Geron Corporation to Present at Banc of America Health Care Conference
MENLO PARK, Calif., May 31, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 11:20 a.m. PDT on Friday, June 1, 2007, at the Banc of America 2007
Toggle Summary Geron Scientists and Collaborators Differentiate Human Embryonic Stem Cells Into Insulin-Producing Islet-Like Clusters
MENLO PARK, Calif., May 17, 2007 –– Geron Corporation (Nasdaq: GERN) today reported that its scientists and collaborators at the University of Alberta have differentiated human embryonic stem cells (hESCs) into islet–like clusters (ILCs) that secrete insulin in response to elevated glucose levels.
Toggle Summary Geron Corporation to Present at Rodman & Renshaw Healthcare Conference
MENLO PARK, Calif., May 11, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 2:55 p.m. CEST (8:55 a.m.
Toggle Summary Geron Corporation to Present at UBS Global Generic & Specialty Pharmaceuticals Conference
Menlo Park, CA – May 7, 2007 –– Geron Corporation (Nasdaq: GERN) will be presenting an update of the company’s product development programs on Tuesday, May 8, 2007, at the UBS Global Generic & Specialty Pharmaceuticals Conference at 9:00 a.m. Eastern Time in New York City.
Toggle Summary Geron Corporation Reports 2007 First Quarter Financial Results
Menlo Park, Calif. – April 27, 2007 – Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2007. For the first quarter of 2007, the company reported operating revenues of $916,000 and operating expenses of $17.3 million, compared to $583,000 and
Toggle Summary Telomerase Presentations at the AACR 2007 Annual Meeting
Menlo Park, CA –– April 25, 2007 –– Geron Corporation (Nasdaq: GERN) today referenced multiple presentations on the role of telomerase and telomeres in cancer at this year’s American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.
Toggle Summary Geron and CXR Conclude Collaboration to Develop In Vitro Assays Using hESC-Derived Hepatocytes
MENLO PARK, Calif., and Dundee, Scotland, April 24, 2007 – Geron Corporation (Nasdaq: GERN) and CXR Biosciences Ltd. today announced the conclusion of a research collaboration that focused on the development of human embryonic stem cell (hESC)–derived hepatocytes for use in in vitro assays of drug
Toggle Summary Studies Confirm Proof-of-Principle for Geron´s Human Embryonic Stem Cell (hESC) Derived Hepatocytes
Findings Published in Cloning and Stem Cells Indicate Utility for Predictive Toxicology Tests MENLO PARK, Calif., April 19, 2007 – Geron Corporation (Nasdaq: GERN) announced today that it has developed standardized hepatocytes from human embryonic stem cells (hESCs) that can model human hepatic
Toggle Summary Geron Supports WARF´s Claims to Human Embryonic Stem Cell Patents
MENLO PARK, Calif., Apr. 2, 2007 – Geron Corporation (Nasdaq: GERN) supports the position of the Wisconsin Alumni Research Foundation (WARF) that U.S. patents covering Dr. James Thomson’s pioneering work with human embryonic stem cells were properly granted.